The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated oxidized regenerated cellulose (ORC) fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.

The present disclosure provides a recombinant collagen and a recombinant collagen sponge material. The recombinant collagen comprises: (a) a protein composed of the amino acid sequence represented by SEQ ID NO: 2; and/or (b) a protein which has the same function as (a) and is derived from (a) by substitution, deletion and/or addition of one or more amino acids in SEQ ID NO:2. The recombinant collagen sponge material is obtained by sequential physical cross-linking and chemical cross-linking of the recombinant collagen. The recombinant collagen sponge material according to the present disclosure is capable of hemostasis, wound surface repair, moisture absorption and platelet aggregation, and has high moisture absorption, a significant hemostatic effect and good biocompatibility, assuming great clinical significance in the field of surgery.

A bleeding control device is provided. The device includes an elongate member with a holding portion and an application portion. A known amount of hemostatic solute within a solution is administered to the application portion and allowed to dry. The elongate member is then sterilized. The resulting bleeding control device may be used during medical procedures such as root canal procedures and others.

Delivery devices, delivery systems, and related methods, for precise administration of hemostatic compositions are disclosed, which may include a trigger mechanism, a pusher, a valve, and a cannula. The pusher is configured to engage with the trigger mechanism, retain a first syringe, a least by coupling with a plunger of the first syringe. The valve is fluidly coupled to the first syringe. The valve is further configured to engage with a second syringe, in fluid communication with both the valve and the first syringe. The cannula extends distally from and is fluidly coupled to the valve. Activation of the trigger mechanism causes the pusher and the plunger of the first syringe to translate in a distal direction, to expel a composition out of the first syringe, through the valve, through the cannula, and out of a distal end of the cannula.

A sheet-shaped tissue adhesive/reinforcement includes a base sheet having biodegradability and a communicative porous structure, and an adhesive resin layer fixed and formed on the base sheet. The adhesive resin layer includes a first reactant made of an aldehyded glycan and a second reactant made of partially carboxylated polylysine, and has a molar ratio of 1 as a ratio of an aldehyde group of the first reactant to an amine group of the second reactant. The adhesive resin layer has a structure of granules derived from powder of the first reactant, and a connecting layer derived from the second reactant. The connecting layer connects the granules to each other and fixes each of the granules onto the base sheet, throughout the sheet-shaped tissue adhesive/reinforcement.

A hemostatic material or a tissue sealant, wherein a main component of the hemostatic material or the tissue sealant or part of the hemostatic material or the tissue sealant is a sponge grown in sea water or fresh water.

Compositions and methods related to flowable hemostats that crosslink during and/or after application to a bleeding site are generally described.

An apparatus and method are disclosed for a biofunctional molecular imprint medical device configured to remain in permanent or temporary contact with a body comprising a supportive structure, a surface material that receives and retains a molecular imprint and that is positioned to contact a body tissue or other substance during use, a molecular imprint of a bioactive molecule wherein an imprinted cavity is of a bioactive molecule that catalyzes the promotion or suppression biological processes and at least one of a semiconductor, a nanoparticle quantum dot, a nano-island, and a quantum wire, wherein the nanoparticle quantum dot, nano-island, or quantum wire produces an electron wave function configuration that dynamically reconfigures the electron charge distribution within the molecular imprint, enabling tuning of the imprinted cavity.

A DOPA-Gelatin is disclosed in which the monophenolic group of tyrosine, a prominent amino acid in porcine gelatin, is converted into a catechol group using an enzyme-based DOPA modification technique. The resulting DOPA-Gelatin has been discovered to exhibit good mechanical strength and adhesion. Moreover, in vitro studies show that DOPA-Gelatin has no cytotoxicity with HDF and HaCaT cells, two cells typically involved in the skin wound healing process. Further RT-PCR and angiogenesis investigation showed that DOPA-Gelatin can promote the expression of wound-related genes and facilitate neovascularization. In a full-thickness dorsal defect model in mice, DOPA-Gelatin treated groups decreased the wound closure time and enhanced hair follicle growth. These results demonstrate that the DOPA-Gelatin hydrogel compositions disclosed herein are an effective functional biomaterial that can potentiate the wound healing process.

This disclosure relates to methods and materials for embolization of one or more blood vessels (e.g., one or more arteries). For example, hydrogel compositions for embolization of one or more blood vessels (e.g., one or more arteries) within a mammal (e.g., a human) are provided.